235 related articles for article (PubMed ID: 26867042)
1. Affective forecasting and medication decision making in breast-cancer prevention.
Hoerger M; Scherer LD; Fagerlin A
Health Psychol; 2016 Jun; 35(6):594-603. PubMed ID: 26867042
[TBL] [Abstract][Full Text] [Related]
2. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Fagerlin A; Dillard AJ; Smith DM; Zikmund-Fisher BJ; Pitsch R; McClure JB; Greene S; Alford SH; Nair V; Hayes DF; Wiese C; Ubel PA
Breast Cancer Res Treat; 2011 Jun; 127(3):681-8. PubMed ID: 21442198
[TBL] [Abstract][Full Text] [Related]
3. My Lived Experiences Are More Important Than Your Probabilities: The Role of Individualized Risk Estimates for Decision Making about Participation in the Study of Tamoxifen and Raloxifene (STAR).
Holmberg C; Waters EA; Whitehouse K; Daly M; McCaskill-Stevens W
Med Decis Making; 2015 Nov; 35(8):1010-22. PubMed ID: 26183166
[TBL] [Abstract][Full Text] [Related]
4. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
Korfage IJ; Fuhrel-Forbis A; Ubel PA; Zikmund-Fisher BJ; Greene SM; McClure JB; Smith DM; Alford SH; Fagerlin A
Breast Cancer Res; 2013; 15(5):R74. PubMed ID: 24004815
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer anxiety's associations with responses to a chemoprevention decision aid.
Dillard AJ; Scherer L; Ubel PA; Smith DM; Zikmund-Fisher BJ; McClure JB; Greene S; Stark A; Fagerlin A
Soc Sci Med; 2013 Jan; 77():13-9. PubMed ID: 23200299
[TBL] [Abstract][Full Text] [Related]
6. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Anderson C; Nichols HB; House M; Sandler DP
Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
[TBL] [Abstract][Full Text] [Related]
7. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.
Nelson HD; Smith ME; Griffin JC; Fu R
Ann Intern Med; 2013 Apr; 158(8):604-14. PubMed ID: 23588749
[TBL] [Abstract][Full Text] [Related]
8. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
[TBL] [Abstract][Full Text] [Related]
9. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Freedman AN; Yu B; Gail MH; Costantino JP; Graubard BI; Vogel VG; Anderson GL; McCaskill-Stevens W
J Clin Oncol; 2011 Jun; 29(17):2327-33. PubMed ID: 21537036
[TBL] [Abstract][Full Text] [Related]
10. Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.
Banegas MP; McClure JB; Barlow WE; Ubel PA; Smith DM; Zikmund-Fisher BJ; Greene SM; Fagerlin A
Patient Educ Couns; 2013 Jun; 91(3):364-71. PubMed ID: 23395006
[TBL] [Abstract][Full Text] [Related]
11. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
12. Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.
Thorneloe RJ; Horne R; Side L; Wolf MS; Smith SG;
Clin Breast Cancer; 2019 Feb; 19(1):e116-e126. PubMed ID: 30518498
[TBL] [Abstract][Full Text] [Related]
13. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
[TBL] [Abstract][Full Text] [Related]
14. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT; Col N; Winer EP; Collyar DE; Cummings SR; Vogel VG; Burstein HJ; Eisen A; Lipkus I; Pfister DG;
J Clin Oncol; 2002 Aug; 20(15):3328-43. PubMed ID: 12149307
[TBL] [Abstract][Full Text] [Related]
15. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N
Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
17. Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.
Vogel VG
Curr Drug Targets; 2011 Dec; 12(13):1874-87. PubMed ID: 21158712
[TBL] [Abstract][Full Text] [Related]
18. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
19. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N
J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
